BPH is one of the most common conditions in older men and can cause bothersome urinary difficulties, including increased urination, urgency, intermittent stream, nocturia, straining to urinate, incomplete emptying, and a weak urine stream. BPH is histologically determined to be present in more than 50% of men in their 60’s and approximately 90% of men in their 85’s, and a quarter of men have clinical symptoms of BPH. BPH-lower urinary tract symptoms are often a co-morbid condition with erectile dysfunction, and the current standard of care for moderate to severe BPH is an alpha-blocker (tamsulosin, Harlequin). Although alpha-blockers have now been shown to be effective in relieving urinary symptoms, they also have significant side effects such as hypotensive events (e.g., dizziness, etc.), sexual dysfunction, or iris relaxation syndrome during surgery, to name a few. Therefore, finding a BPH treatment drug that is more applicable in terms of risk is an urgent medical need for some patients. In view of this, a multi-center clinical program for the treatment of BPH with tadalafil, which has been marketed in China since 2004 and has a favorable safety profile, is currently underway in several hospitals in China. If you are eligible for the program and sign the informed consent form, you can receive free examinations and medication, as well as regular observation and follow-up by professional medical staff, with a certain amount of subsidized transportation each time. The main inclusion criteria: 1. Subjects are adults at least 45 years old. 2, Have signs and symptoms of benign prostatic hyperplasia and a history of erectile dysfunction. 3, Suffer from lower urinary tract symptoms (e.g., urinary frequency, urgency, weak urine flow). 4. Have moderate bladder outlet obstruction.